INFIQ Stock Price, Chart, Stats & News
Infinity Pharmaceuticals, Inc. (INFIQ) does not currently pay a dividend.
INFIQ chart
Fundamentals
Gross margin | 39.72% |
Operating margin | -1729.43% |
Pretax margin | -1711.11% |
Net margin | -1711.11% |
Effective tax rate | – |
ROA | -105.26% |
ROE | -3521.35% |
D/E | -2.53x |
Interest coverage ratio | -249.13x |
INFIQ valuation
P/E | – |
P/S | 0.00x |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.22x |
About
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F.
Similar securities
Based on sector and market capitalization
